FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220885711> ?p ?o ?g. }

• W4220885711 endingPage "e1130" @default.
• W4220885711 startingPage "e1130" @default.
• W4220885711 abstract "Background and Objectives Improved biomarkers of neuroprotective treatment are needed in progressive multiple sclerosis (PMS) to facilitate more efficient phase 2 trial design. The MS-STAT randomized controlled trial supported the neuroprotective potential of high-dose simvastatin in secondary progressive MS (SPMS). Here, we analyze serum from the MS-STAT trial to assess the extent to which neurofilament light (NfL) and neurofilament heavy (NfH), both promising biomarkers of neuroaxonal injury, may act as biomarkers of simvastatin treatment in SPMS. Methods The MS-STAT trial randomized patients to 80 mg simvastatin or placebo. Serum was analyzed for NfL and NfH using Simoa technology. We used linear mixed models to investigate the treatment effects of simvastatin compared with placebo on NfL and NfH. Additional models examined the relationships between neurofilaments and MRI and clinical measures of disease severity. Results A total of 140 patients with SPMS were included. There was no evidence for a simvastatin treatment effect on NfL or NfH: compared with placebo, NfL was 1.2% lower (95% CI 10.6% lower to 9.2% higher; p = 0.820) and NfH was 0.4% lower (95% CI 18.4% lower to 21.6% higher; p = 0.969) in the simvastatin treatment group. Secondary analyses suggested that higher NfL was associated with greater subsequent whole brain atrophy, higher T2 lesion volume, and more new/enlarging T2 lesions in the previous 12 months, as well as greater physical disability. There were no significant associations between NfH and MRI or clinical variables. Discussion We found no evidence of a simvastatin treatment effect on serum neurofilaments. While confirmation of the neuroprotective benefits of simvastatin is awaited from the ongoing phase 3 study ( NCT03387670 ), our results suggest that treatments capable of slowing the rate of whole brain atrophy in SPMS, such as simvastatin, may act via mechanisms largely independent of neuroaxonal injury, as quantified by NfL. This has important implications for the design of future phase 2 clinical trials in PMS. Trial Registration Information MS-STAT: NCT00647348 . Classification of Evidence This study provides class I evidence that simvastatin treatment does not have a large impact on either serum NfL or NfH, as quantified in this study, in SPMS." @default.
• W4220885711 created "2022-04-03" @default.
• W4220885711 creator A5007196021 @default.
• W4220885711 creator A5017802095 @default.
• W4220885711 creator A5032787992 @default.
• W4220885711 creator A5036742639 @default.
• W4220885711 creator A5044136330 @default.
• W4220885711 creator A5048113582 @default.
• W4220885711 creator A5053098162 @default.
• W4220885711 creator A5073721007 @default.
• W4220885711 creator A5079766290 @default.
• W4220885711 creator A5082858310 @default.
• W4220885711 date "2022-01-14" @default.
• W4220885711 modified "2023-09-26" @default.
• W4220885711 title "Assessing Neurofilaments as Biomarkers of Neuroprotection in Progressive Multiple Sclerosis" @default.
• W4220885711 cites W1567125068 @default.
• W4220885711 cites W1998299241 @default.
• W4220885711 cites W2010854663 @default.
• W4220885711 cites W2026225517 @default.
• W4220885711 cites W2028067695 @default.
• W4220885711 cites W2045680585 @default.
• W4220885711 cites W2052994550 @default.
• W4220885711 cites W2058234840 @default.
• W4220885711 cites W2096967123 @default.
• W4220885711 cites W2105206040 @default.
• W4220885711 cites W2129379212 @default.
• W4220885711 cites W2142577589 @default.
• W4220885711 cites W2144594869 @default.
• W4220885711 cites W2144969187 @default.
• W4220885711 cites W2154727081 @default.
• W4220885711 cites W2549644306 @default.
• W4220885711 cites W2624142896 @default.
• W4220885711 cites W2766371671 @default.
• W4220885711 cites W2886710738 @default.
• W4220885711 cites W2888865579 @default.
• W4220885711 cites W2944092461 @default.
• W4220885711 cites W2945865866 @default.
• W4220885711 cites W2946911440 @default.
• W4220885711 cites W2950228559 @default.
• W4220885711 cites W3008600501 @default.
• W4220885711 cites W3021612937 @default.
• W4220885711 cites W3026936125 @default.
• W4220885711 cites W3042931334 @default.
• W4220885711 cites W3093214985 @default.
• W4220885711 cites W3132472946 @default.
• W4220885711 cites W3133335727 @default.
• W4220885711 cites W3164945483 @default.
• W4220885711 cites W4292528167 @default.
• W4220885711 doi "https://doi.org/10.1212/nxi.0000000000001130" @default.
• W4220885711 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35031587" @default.
• W4220885711 hasPublicationYear "2022" @default.
• W4220885711 type Work @default.
• W4220885711 citedByCount "11" @default.
• W4220885711 countsByYear W42208857112022 @default.
• W4220885711 countsByYear W42208857112023 @default.
• W4220885711 crossrefType "journal-article" @default.
• W4220885711 hasAuthorship W4220885711A5007196021 @default.
• W4220885711 hasAuthorship W4220885711A5017802095 @default.
• W4220885711 hasAuthorship W4220885711A5032787992 @default.
• W4220885711 hasAuthorship W4220885711A5036742639 @default.
• W4220885711 hasAuthorship W4220885711A5044136330 @default.
• W4220885711 hasAuthorship W4220885711A5048113582 @default.
• W4220885711 hasAuthorship W4220885711A5053098162 @default.
• W4220885711 hasAuthorship W4220885711A5073721007 @default.
• W4220885711 hasAuthorship W4220885711A5079766290 @default.
• W4220885711 hasAuthorship W4220885711A5082858310 @default.
• W4220885711 hasBestOaLocation W42208857111 @default.
• W4220885711 hasConcept C126322002 @default.
• W4220885711 hasConcept C142724271 @default.
• W4220885711 hasConcept C143998085 @default.
• W4220885711 hasConcept C203014093 @default.
• W4220885711 hasConcept C204787440 @default.
• W4220885711 hasConcept C25498285 @default.
• W4220885711 hasConcept C27081682 @default.
• W4220885711 hasConcept C2776329913 @default.
• W4220885711 hasConcept C2780640218 @default.
• W4220885711 hasConcept C2781172350 @default.
• W4220885711 hasConcept C535046627 @default.
• W4220885711 hasConcept C71924100 @default.
• W4220885711 hasConceptScore W4220885711C126322002 @default.
• W4220885711 hasConceptScore W4220885711C142724271 @default.
• W4220885711 hasConceptScore W4220885711C143998085 @default.
• W4220885711 hasConceptScore W4220885711C203014093 @default.
• W4220885711 hasConceptScore W4220885711C204787440 @default.
• W4220885711 hasConceptScore W4220885711C25498285 @default.
• W4220885711 hasConceptScore W4220885711C27081682 @default.
• W4220885711 hasConceptScore W4220885711C2776329913 @default.
• W4220885711 hasConceptScore W4220885711C2780640218 @default.
• W4220885711 hasConceptScore W4220885711C2781172350 @default.
• W4220885711 hasConceptScore W4220885711C535046627 @default.
• W4220885711 hasConceptScore W4220885711C71924100 @default.
• W4220885711 hasIssue "2" @default.
• W4220885711 hasLocation W42208857111 @default.
• W4220885711 hasLocation W42208857112 @default.
• W4220885711 hasLocation W42208857113 @default.
• W4220885711 hasLocation W42208857114 @default.
• W4220885711 hasOpenAccess W4220885711 @default.
• W4220885711 hasPrimaryLocation W42208857111 @default.

• next